circle

INVESTORS & MEDIA

INVESTOR OVERVIEW

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. More >>

ANNUAL REPORT

CORPORATE PRESENTATION

CYTOKINETICS FACT SHEETS

fact1

Company

09/21/18
( FY )
ALS

ALS

03/11/18
( FY )
SMA

SMA

07/13/18
( FY )

NEWS

Date Title and Summary
Toggle Summary Cytokinetics Announces Preclinical Data for CK-3828136 to Be Presented at the 2021 Medicinal Chemistry Gordon Research Conference
SOUTH SAN FRANCISCO, Calif. , Oct. 21, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that data relating to the discovery and optimization of CK-3828136 (CK-136) will be presented at the 2021 Medicinal Chemistry Gordon Research Conference , taking place in West
Toggle Summary Cytokinetics to Announce Third Quarter Results on November 3, 2021
SOUTH SAN FRANCISCO, Calif. , Oct. 20, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report third quarter results on November 3, 2021 at 4:00 PM Eastern Time . Following the announcement, Cytokinetics’ senior management will host a
Toggle Summary Cytokinetics Outlines Go-To-Market Strategy for Omecamtiv Mecarbil and Provides Updates on Cardiovascular Pipeline at Today’s Analyst & Investor Day
Go-To-Market Strategy Focuses on Educating Healthcare Professionals, Ensuring Managed Care Access, and Enacting Programs for Patient Access, Education and Support Clinical Trial Design Announced for SEQUOIA-HCM,  Phase 3 Clinical Trial of Aficamten Expected to Begin in Q4 Company Details Plan for
Toggle Summary Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif. , Oct. 01, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on September 30, 2021 it granted stock options to purchase an aggregate of 206,300 shares of common stock to 14 new employees, whose employment commenced in September 2021

EVENTS

There are currently no events to display.